{"title":"达帕格列净对 II 型糖尿病高血压患者的降压作用","authors":"Samah Hammoud, Arige Boubou, Nisrin Kaddar","doi":"10.52711/0974-360x.2024.00128","DOIUrl":null,"url":null,"abstract":"Hypertension (HTN) and type II diabetes mellitus (T2DM) are two main cardiovascular risk factors that coexist frequently. The aim of this study is evaluation the antihypertensive effect of dapagliflozin in hypertensive type 2 diabetic patients (controlled/inadequately uncontrolled), and study its effect on contributing factors in that effectiveness (ex. weight loss and SNS damping). Primary endpoints included the effect of dapagliflozin on hemoglobin A1C (HbA1c) and blood pressure. Secondary endpoints included the effect of drug on weight body, pulse rate and pulse pressure. Patients were randomly selected from the outpatient of the Endocrinology Department at Tishreen University Hospital in Syria, and divided into two groups: dapagliflozin group (n=45) received 5 or 10mg dapagliflozin once daily as an add-on therapy to oral anti-diabetic drugs (OAD)and antihypertensive drugs, and control group (n=38) received OAD and antihypertensive drugs. After 12 weeks follow-up, dapagliflozin-treated versus control-treated showed significant reduction in HbA1C (-0.7% vs -0.3%, p<0.05, mean seated SBP (-9.4 vs -1.2mmHg, p=0.0001) and mean seated DBP(-6 vs-0.3mmHg, p=0.0001). Dapagliflozin also reduced body weight compared with control (-2.6 vs -0.6kg, p=0.0001) andthere was a significant positive correlation between weight loss and BP reduction. The effect on pulse rate was modest and similar between two groups but dapagliflozin have lowered pulse pressure values. There was no significant dose-response with any studied parameter, too. 5mg dapagliflozin once daily improved glycemic control, reduced body weight, SBP more than DBP and thus improved pulse pressure. All that without any significant effect on pulse rate.","PeriodicalId":21141,"journal":{"name":"Research Journal of Pharmacy and Technology","volume":"84 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Antihypertensive effect of Dapagliflozin in Type II diabetic patients with Hypertension\",\"authors\":\"Samah Hammoud, Arige Boubou, Nisrin Kaddar\",\"doi\":\"10.52711/0974-360x.2024.00128\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Hypertension (HTN) and type II diabetes mellitus (T2DM) are two main cardiovascular risk factors that coexist frequently. The aim of this study is evaluation the antihypertensive effect of dapagliflozin in hypertensive type 2 diabetic patients (controlled/inadequately uncontrolled), and study its effect on contributing factors in that effectiveness (ex. weight loss and SNS damping). Primary endpoints included the effect of dapagliflozin on hemoglobin A1C (HbA1c) and blood pressure. Secondary endpoints included the effect of drug on weight body, pulse rate and pulse pressure. Patients were randomly selected from the outpatient of the Endocrinology Department at Tishreen University Hospital in Syria, and divided into two groups: dapagliflozin group (n=45) received 5 or 10mg dapagliflozin once daily as an add-on therapy to oral anti-diabetic drugs (OAD)and antihypertensive drugs, and control group (n=38) received OAD and antihypertensive drugs. After 12 weeks follow-up, dapagliflozin-treated versus control-treated showed significant reduction in HbA1C (-0.7% vs -0.3%, p<0.05, mean seated SBP (-9.4 vs -1.2mmHg, p=0.0001) and mean seated DBP(-6 vs-0.3mmHg, p=0.0001). Dapagliflozin also reduced body weight compared with control (-2.6 vs -0.6kg, p=0.0001) andthere was a significant positive correlation between weight loss and BP reduction. The effect on pulse rate was modest and similar between two groups but dapagliflozin have lowered pulse pressure values. There was no significant dose-response with any studied parameter, too. 5mg dapagliflozin once daily improved glycemic control, reduced body weight, SBP more than DBP and thus improved pulse pressure. All that without any significant effect on pulse rate.\",\"PeriodicalId\":21141,\"journal\":{\"name\":\"Research Journal of Pharmacy and Technology\",\"volume\":\"84 3\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-02-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Research Journal of Pharmacy and Technology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.52711/0974-360x.2024.00128\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research Journal of Pharmacy and Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52711/0974-360x.2024.00128","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0
摘要
高血压(HTN)和 II 型糖尿病(T2DM)是经常并存的两大心血管风险因素。本研究旨在评估达帕格列净对高血压 2 型糖尿病患者(已控制/未充分控制)的降压效果,并研究其对降压效果的影响因素(如体重减轻和 SNS 阻尼)。主要终点包括达帕格列净对血红蛋白 A1C (HbA1c) 和血压的影响。次要终点包括药物对体重、脉率和脉压的影响。患者从叙利亚 Tishreen 大学医院内分泌科门诊随机抽取,分为两组:达帕格列净组(45 人)接受 5 毫克或 10 毫克达帕格列净,每天一次,作为口服抗糖尿病药物(OAD)和降压药物的附加疗法;对照组(38 人)接受 OAD 和降压药物。随访12周后,达帕格列净治疗组与对照组相比,HbA1C显著降低(-0.7% vs -0.3%,p<0.05),平均坐位SBP显著降低(-9.4 vs -1.2 mmHg,p=0.0001),平均坐位DBP显著降低(-6 vs-0.3 mmHg,p=0.0001)。与对照组相比,达帕格列净还能减轻体重(-2.6 vs -0.6kg,p=0.0001),体重减轻与血压降低呈显著正相关。对脉搏率的影响不大,两组之间相似,但达帕格列净降低了脉压值。任何研究参数也没有明显的剂量反应。每日一次服用 5 毫克达帕格列净可改善血糖控制、减轻体重、降低 SBP 多于 DBP,从而改善脉压。但所有这些对脉搏率均无明显影响。
Antihypertensive effect of Dapagliflozin in Type II diabetic patients with Hypertension
Hypertension (HTN) and type II diabetes mellitus (T2DM) are two main cardiovascular risk factors that coexist frequently. The aim of this study is evaluation the antihypertensive effect of dapagliflozin in hypertensive type 2 diabetic patients (controlled/inadequately uncontrolled), and study its effect on contributing factors in that effectiveness (ex. weight loss and SNS damping). Primary endpoints included the effect of dapagliflozin on hemoglobin A1C (HbA1c) and blood pressure. Secondary endpoints included the effect of drug on weight body, pulse rate and pulse pressure. Patients were randomly selected from the outpatient of the Endocrinology Department at Tishreen University Hospital in Syria, and divided into two groups: dapagliflozin group (n=45) received 5 or 10mg dapagliflozin once daily as an add-on therapy to oral anti-diabetic drugs (OAD)and antihypertensive drugs, and control group (n=38) received OAD and antihypertensive drugs. After 12 weeks follow-up, dapagliflozin-treated versus control-treated showed significant reduction in HbA1C (-0.7% vs -0.3%, p<0.05, mean seated SBP (-9.4 vs -1.2mmHg, p=0.0001) and mean seated DBP(-6 vs-0.3mmHg, p=0.0001). Dapagliflozin also reduced body weight compared with control (-2.6 vs -0.6kg, p=0.0001) andthere was a significant positive correlation between weight loss and BP reduction. The effect on pulse rate was modest and similar between two groups but dapagliflozin have lowered pulse pressure values. There was no significant dose-response with any studied parameter, too. 5mg dapagliflozin once daily improved glycemic control, reduced body weight, SBP more than DBP and thus improved pulse pressure. All that without any significant effect on pulse rate.
期刊介绍:
Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal, devoted to pharmaceutical sciences. The aim of RJPT is to increase the impact of pharmaceutical research both in academia and industry, with strong emphasis on quality and originality. RJPT publishes Original Research Articles, Short Communications, Review Articles in all areas of pharmaceutical sciences from the discovery of a drug up to clinical evaluation. Topics covered are: Pharmaceutics and Pharmacokinetics; Pharmaceutical chemistry including medicinal and analytical chemistry; Pharmacognosy including herbal products standardization and Phytochemistry; Pharmacology: Allied sciences including drug regulatory affairs, Pharmaceutical Marketing, Pharmaceutical Microbiology, Pharmaceutical biochemistry, Pharmaceutical Education and Hospital Pharmacy.